StockNews.AI
TARS
StockNews.AI
180 days

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

1. Tarsus will host a live webcast on Feb 25, 2025. Event details soon. 2. Q4 and full-year 2024 financial results will be reported. Update expected. 3. XDEMVY FDA approval and new pipeline projects are highlighted. Pipeline progress noted. 4. Webcast recording available for 90 days. Accessibility ensured.

Earnings
-1.81%Current Return
VS
-1.72%S&P 500
$48.7202/20 05:07 PM EDTEvent Start
$47.8402/21 11:25 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Earnings call announcements typically set investor expectations but reveal no new fundamental shifts before the actual report. Historical patterns show mixed reactions until financial data is disclosed.

How important is it?

This event is significant because it provides updated financial performance and pipeline details that could influence investor sentiment. However, the actual impact remains contingent on the forthcoming data.

Why Short Term?

The imminent release of quarterly results is likely to yield short-term volatility. Post-announcement movements will depend on performance metrics disclosed during the call.

Related Companies

TARS
February 20, 2025 17:00 ET  | Source: Tarsus Pharmaceuticals, Inc IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801AKemp@tarsusrx.com Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@tarsusrx.com

Related News